Therapeutic effect of tyndallized Lactobacillus rhamnosus IDCC 3201 on atopic dermatitis mediated by down‐regulation of immunoglobulin E in NC/Nga mice. (July 2016)

• Record Type: Journal Article
• Authors: Lee, Seung‐Hun; Yoon, Jong‐Min; Kim, Young‐Hoo; Jeong, Dong‐Gu; Park, Soobong; Kang, Dae‐Jung
• Is Part Of: Microbiology and immunology. Volume 60:Number 7(2016:Jul.)
• Page Start: 468
• Page End: 476
• Publication Date: 2016-07
• Subjects: atopic dermatitis -- immunoglobulin E -- Lactobacillus rhamnosus -- tyndallization; Microbiology -- Periodicals; Immunology -- Periodicals; Allergy and Immunology -- Periodicals; Microbiology -- Periodicals; Microbiologie -- Périodiques; Immunologie -- Périodiques; 579
• DOI: 10.1111/1348-0421.12390
• Languages: English
• ISSNs: 0385-5600

Abstract

ABSTRACT: The therapeutic effect of oral administration of Lactobacillus rhamnosus IDCC 3201 tyndallizate (RHT3201) on atopic dermatitis (AD)‐like skin lesions in NC/Nga mice were investigated. After induction of dermatitis in NC/Nga mice with house‐dust mite extract, each group was fed RHT3201 with 1 × 10 8, 1 × 10 9, or 1 × 10 10 cells orally once a day for 8 weeks. Dermatitis scores and frequency of scratching were improved by oral feeding with RHT3201. In contrast to the control group, RHT3201‐fed mice showed significantly down‐regulated mast cell numbers and serum immunoglobulin E (IgE) concentrations had significantly less IL4 in their axillary lymph node cells. The therapeutic effect of RHT3201 was found to be dose‐dependent. These findings indicate that RHT3201 has potential for treating AD.